Clinical Course of Six Children With GNAO1 Mutations Causing a Severe and Distinctive Movement Disorder-Reference-Cited by-同舟云学术

Clinical Course of Six Children With GNAO1 Mutations Causing a Severe and Distinctive Movement Disorder

Published:2016-06 Issue: Volume:59 Page:81-84
ISSN:0887-8994
Container-title:Pediatric Neurology
language:en
Short-container-title:Pediatric Neurology

Author:

Ananth Amitha L.,Robichaux-Viehoever Amy,Kim Young-Min,Hanson-Kahn Andrea,Cox Rachel,Enns Gregory M.,Strober Jonathan,Willing Marcia,Schlaggar Bradley L.,Wu Yvonne W.,Bernstein Jonathan A.

Publisher

Elsevier BV

Subject

Clinical Neurology,Developmental Neuroscience,Neurology,Pediatrics, Perinatology, and Child Health

Reference11 articles.

1. Molecular mechanisms of go signaling;Jiang;Neurosignals,2009

2. De novo mutations in GNAO1, encoding a Galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy;Nakamura;Am J Hum Genet,2013

3. Phenotypic spectrum of GNAO1 variants: epileptic encephalopathy to involuntary movements with severe developmental delay;Saitsu;Eur J Hum Genet,2016

4. Progressive movement disorder in brothers carrying a GNAO1 mutation responsive to deep brain stimulation;Kulkarni;J Child Neurol,2016

5. Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy;Law;Clin Chim Acta,2015

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation;Movement Disorders;2024-06-16

2. AAV9-Mediated Intrastriatal Delivery ofGNAO1Reduces Hyperlocomotion inGnao1Heterozygous R209H Mutant Mice;Journal of Pharmacology and Experimental Therapeutics;2024-06-12

3. Dyskinetic crisis in GNAO1-related disorders: clinical perspectives and management strategies;Frontiers in Neurology;2024-06-06

4. Adult‐Onset Dystonia and Hypertrophic Cardiomyopathy in Patient with a De Novo 16q12.2q21 Deletion;Movement Disorders;2024-04-23

5. Molecular Dynamic Simulations to Determine Individualized Therapy: Tetrabenazine for the GNAO1 Encephalopathy E246K Variant;Molecular Diagnosis & Therapy;2024-04-06